Abstract: Objective : To study the inhibiting effect of anti-vascular endothelial growth factor andreceptor antilxdy on the growth and metastasis of gastric cancer. Methods : 1、Anti-VEGF antibodyand anti-VEDR antibody were added at various concentrations to the culture medium respectively. After5 days, the growth of BGC-823 was measured by MTT assay. 2、The anti-umor and anti-metastasiseffect of anti-VEGF antibody, anti-DEDR antibody were investigated by means of an orthotopic xeno-transplanted model of human gastric cancer BGC-823 in male mice which had been randumly dividedinto 4 groups: control group reeiving PBS, group receving 50ug/mice anti-VEGF antibody, group receiving SOug/mice anti-VEDR antibody, and group reeiving SOug/mice anti-VEAF antibody and anti-VEDR antibody. Anti-VEGF antibody and anti-VEDR antibody was given i.p. twice a week for 8 weeksfrom day 7 after transplantation. All animals were sacrificed at the end of 10 weeks. The tumor wasweighted and the intra-tumoral microvessed density(MVD) was recorded, and the liver was histological-1y examined in order to discover micrometastasis. Results : 1. The addition of anti-VEGF antibody andanti-VEDR antibody at various concentration had different inhibitory effect on BGC-823. 2、1)Both anti-VEGF antibody and anti-VEDR antibody showed a significant inhibitory effect on the growth of primary tumors, in the combination treatment group the inhibitory effectwas more significant than single agent.2)Liver metastasis developed in 80% of the controls, in 2 of 12 mice (16.7%)reiving anti-VEGF an-tffbody, in 3 of 12 mice (25%) anti-VEDR antibody and none reiving combination treatment. 3)In con-trast with the control group MVD was less significant in the other groups. Conclusions : Both blockadi-age of VEGF with anti-VEGF antibody and blockadiage of VEGF-binding site with anti-VEGF anti-body could inhibited BGC-823 growth. They might provide a new approach to the treatment of gastriccancer.